about
Lipid-based formulations for intestinal lymphatic delivery.Cationic and PEGylated Amphiphilic Cyclodextrins: Co-Formulation Opportunities for Neuronal Sirna DeliveryTherapeutic targeting in the silent era: advances in non-viral siRNA delivery.Pattern recognition receptors--molecular orchestrators of inflammation in inflammatory bowel disease.Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer?Non-viral nanosystems for gene and small interfering RNA delivery to the central nervous system: formulating the solution.The role of transcription factors in prostate cancer and potential for future RNA interference therapy.Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia.Delivering a disease-modifying treatment for Huntington's disease.Nanoparticles and the blood-brain barrier: advancing from in-vitro models towards therapeutic significance.RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies.RNA interference for multiple myeloma therapy: targeting signal transduction pathways.Life in 3D is never flat: 3D models to optimise drug delivery.Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate.Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.Bioconjugated gold nanoparticles enhance cellular uptake: A proof of concept study for siRNA delivery in prostate cancer cells.A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor.Lipid-based nanocarriers for oral peptide delivery.7-formyl-10-methylisoellipticine, a novel ellipticine derivative, induces mitochondrial reactive oxygen species (ROS) and shows anti-leukaemic activity in mice.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological diseaseEvaluation of the physicochemical properties and the biocompatibility of polyethylene glycol-conjugated gold nanoparticles: A formulation strategy for siRNA delivery.The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics.Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs.Cyclodextrin mediated delivery of NF-κB and SRF siRNA reduces the invasion potential of prostate cancer cells in vitro.Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: in vitro analysis.Oligonucleotide conjugates - Candidates for gene silencing therapeutics.Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.Early-stage development of novel cyclodextrin-siRNA nanocomplexes allows for successful postnebulization transfection of bronchial epithelial cells.Differential nanotoxicological and neuroinflammatory liabilities of non-viral vectors for RNA interference in the central nervous system.Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system.In vitro investigations of the efficacy of cyclodextrin-siRNA complexes modified with lipid-PEG-Octaarginine: towards a formulation strategy for non-viral neuronal siRNA delivery.Characterisation of cationic amphiphilic cyclodextrins for neuronal delivery of siRNA: effect of reversing primary and secondary face modifications.Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice.Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate.A click chemistry route to 2-functionalised PEGylated and cationic β-cyclodextrins: co-formulation opportunities for siRNA delivery.Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo.Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.Evaluation of cellular uptake and gene transfer efficiency of pegylated poly-L-lysine compacted DNA: implications for cancer gene therapy.Gold nanoparticles enlighten the future of cancer theranostics.Cell transfection with polycationic cyclodextrin vectors.
P50
Q34660960-77ED79E9-B84D-4DC6-8903-BBAC75C41EDDQ34785349-39D1F4AA-EB74-4305-BCA5-C027E2C75232Q37739831-3A68CF91-A08F-4593-9859-C6E6D9D32626Q38055920-AAB3B99E-4B43-42E5-AC6A-2E3AEC44D565Q38090207-A255F0ED-87B7-49F8-AE22-8A95F880AB4FQ38124773-F55D44C1-C8A5-4DB1-B870-6C09C9197C44Q38198726-42C3ED85-6587-44DE-84B0-11E8A2FF17D9Q38248891-19B5E4BE-C328-4E3D-A437-5FBA17B22A52Q38254403-A7306F93-C1B8-4844-8198-B6EA66855F06Q38275050-BFFA7CF5-CA22-413E-B578-9BC3A243971BQ38541950-4F9F696D-E928-4B7B-AEC5-B7A91A1EBB48Q38550480-15C87FDF-4892-48A5-976C-6B0FEE56AE7CQ38556582-D6845AF4-B7D0-42A6-83E5-20030FD0418EQ38669102-D6AB1AC0-890C-40C5-B9F9-AC61E213451DQ38718484-D4820029-827C-4685-8399-605934EA0200Q38770339-7676985F-146E-4EDE-865B-5CD7E114AC38Q38807392-211C60BA-8421-4679-A932-FBFB04CDFB81Q38808878-D6F3A25D-E1A7-431B-A7F8-8661324607E4Q38820155-970B7B6C-55E6-4614-A3E9-C31F509AC8B3Q38831232-614793AD-9DB1-4C6E-A63C-21137D98908CQ38839424-5A8B40B4-6A2F-477C-A137-B953AE95BF30Q38850821-BB152014-C9A0-48EB-A4C7-44D0B32DB09DQ38851153-D7035A4F-990B-49CA-B49C-F3F74C59BE1CQ38871314-8C353051-AB10-453B-8C2E-85EEFC6FF8F8Q38907247-C6455653-4067-43C0-93C3-B09E9E11F64DQ38926959-71C07A28-EEFC-42FD-89C9-86AF82A1D3DDQ38980618-BF2B4CAD-FEFC-4A10-A90E-76ABFB92FFE0Q39012050-C2123F97-EC34-4E31-B8E7-740E8D2B691EQ39076959-5B42AE8F-FBC7-402D-B2B2-D0BD0015E2D2Q39180119-88F45DCF-F95D-4F6D-8339-DBAA3B018011Q39236255-3C28BEF9-BB9F-48BF-8C2C-9A69D044ACFFQ39269269-B57B26FB-EBF2-42FA-BAE2-490BC66F460BQ39308895-B668E25A-413E-4F7B-8589-18C1BE7417F5Q39322094-14BA6F6F-6FE5-48D1-B809-214FB37A113EQ39615047-79101ED1-DE5E-47A1-B093-668EC2F27A89Q39623350-D4903295-A151-4003-ADA4-8B1C78AF903FQ40141200-8DC5B9F8-F85E-481D-B052-27AF66F0D907Q40264444-7EC2CCF1-7B37-4AC0-BE1C-B8D74DA73376Q41545901-FF067601-A51A-4239-B750-A3C87F37386DQ41914231-63928618-6637-4D53-BA01-022F48DB4ABB
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Caitriona M O'Driscoll
@ast
Caitriona M O'Driscoll
@en
Caitriona M O'Driscoll
@es
Caitriona M O'Driscoll
@sl
type
label
Caitriona M O'Driscoll
@ast
Caitriona M O'Driscoll
@en
Caitriona M O'Driscoll
@es
Caitriona M O'Driscoll
@sl
altLabel
Caitriona M O'Driscoll
@en
prefLabel
Caitriona M O'Driscoll
@ast
Caitriona M O'Driscoll
@en
Caitriona M O'Driscoll
@es
Caitriona M O'Driscoll
@sl
P214
P106
P1153
7007040321
P21
P214
P31
P496
0000-0002-6915-6201
P734
P7859
viaf-315726799